Acadia Pharmaceuticals Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ACAD, updated each market day.
ACAD AI Sentiment
AI predicts Acadia Pharmaceuticals Inc. stock is likely to decrease over the next 10 market days.
Prediction date: June 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Sector
Exchange
Market Cap
$4,061,714,836
Cap Tier
Employees
798
Headquarters
SAN DIEGO, CA
Listed Since
May 27, 2004
Website
ACAD Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ACAD Volatility
Acadia Pharmaceuticals Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
